

HR 2863

Cell Development Research Act of 2001

Congress: 107 (2001–2003, Ended)

Chamber: House Policy Area: Health Introduced: Sep 6, 2001

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Sep 17, 2001) **Official Text:** https://www.congress.gov/bill/107th-congress/house-bill/2863

Sponsor

Name: Rep. McDermott, Jim [D-WA-7]

Party: Democratic • State: WA • Chamber: House

Cosponsors (17 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Evans, Lane [D-IL-17]	$D \cdot IL$		Sep 6, 2001
Rep. Abercrombie, Neil [D-HI-1]	$D \cdot HI$		Sep 13, 2001
Rep. Kleczka, Gerald D. [D-WI-4]	$D\cdotWI$		Sep 13, 2001
Rep. Langevin, James R. [D-RI-2]	$D \cdot RI$		Sep 13, 2001
Rep. Sandlin, Max [D-TX-1]	$D \cdot TX$		Sep 13, 2001
Rep. Stark, Fortney Pete [D-CA-13]	D · CA		Sep 13, 2001
Rep. Wynn, Albert Russell [D-MD-4]	$D\cdotMD$		Sep 13, 2001
Rep. Capuano, Michael E. [D-MA-8]	$D \cdot MA$		Sep 21, 2001
Rep. Eshoo, Anna G. [D-CA-14]	D · CA		Sep 21, 2001
Rep. Filner, Bob [D-CA-50]	D · CA		Sep 21, 2001
Rep. Frank, Barney [D-MA-4]	$D \cdot MA$		Oct 9, 2001
Rep. Kilpatrick, Carolyn C. [D-MI-15]	$D\cdotMI$		Oct 9, 2001
Rep. Schakowsky, Janice D. [D-IL-9]	$D \cdot IL$		Dec 5, 2001
Rep. Carson, Julia [D-IN-10]	$D \cdot IN$		Feb 26, 2002
Rep. Holt, Rush [D-NJ-12]	D · NJ		Mar 13, 2002
Rep. McGovern, James P. [D-MA-3]	$D \cdot MA$		May 22, 2002
Rep. McKinney, Cynthia A. [D-GA-4]	D · GA		Jun 13, 2002

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 17, 2001

Subjects & Policy Tags
Policy Area:
Health
Related Bills
No related bills are listed.
Summary (as of Sep 6, 2001)
Cell Development Research Act of 2001 - Amends the Federal Food, Drug, and Cosmetic Act to provide for the establishment and maintenance of a single panel in the Food and Drug Administration to: (1) provide expert scientific advice and recommendations in the field of cell development, including advice and recommendations regarding any clinical investigation of a drug developed as a result of research in the field of embryology and any approval for marketing of such a drug; and (2) make policy recommendations with the goal of promoting research in the field of cell development. Prohibits the panel making recommendations regarding the practice of fertility medicine.
Actions Timeline
 Sep 17, 2001: Referred to the Subcommittee on Health. Sep 6, 2001: Introduced in House Sep 6, 2001: Referred to the House Committee on Energy and Commerce.